TABLE 3.

Summary of adverse events.

Adverse event		SAD/Adult								SAD elderly (Part A)			MAD
System organ class (SOC)	Preferred term (PT)	TRC150094 5-400 mg n (%)							Placebo	TRC150094		Placebo	TRC150094		Placebo (N = 7) n (%)
		5a mg (N = 6)	25b mg (N = 6)	50c mg (N = 6)	100a mg (N = 6)	200b mg (N = 6)	400c mg (N = 6)	All (N = 36)	(N = 12) n (%)	50 mg (N = 12)	150 mg (N = 12)	(N = 8) n (%)	50 mg (N = 12) n (%)	150 mg (N = 9) n (%)
No. of subjects reporting at least one AEs post-treatment		0	1 (16.7)	2 (33.3)	1 (16.7)	2 (33.3)	1 (16.7)	7 (19.4)	1 (8.3)	3 (25.0)	0	0	0	1 (11.1)	1 (14.3)
Metabolism and Nutrition	Decreased Appetite	0	0	0	0	1 (16.7)	1 (16.7)	2 (5.6)	1 (8.3)	0	0	0	0	0	0
Musculoskeletal and Connective Tissue Disorders	Back Pain	0	0	0	0	0	1 (16.7)	1 (2.8)	1 (8.3)	1 (8.3)	0	0	0	0	0
	Myalgia	0	0	1 (16.7)	0	0	0	1 (2.8)	0	0	0	0	0	0	0
	Pain in Extremity	0	0	0	0	1 (16.7)	1 (16.7)	2 (5.6)	0	0	0	0	0	0	0
Nervous System Disorders	Dizziness Postural	0	1 (16.7)	0	1 (16.7)	0	0	2 (5.6)	0	0	0	0	0	0	0
	Headache	0	0	1 (16.7)	0	1 (16.7)	1 (16.7)	3 (8.3)	0	1 (8.3)	0	0	0	0	0
General disorders and administration site conditions	Pyrexia	0	0	0	0	0	0	0	0	0	0	0	0	1 (11.1)	0
Respiratory, thoracic, and mediastinal disorders	Cough	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (14.3)

N=Number of subjects with non-missing values; n/% = Number/percentage of subjects with the given characteristics.

^aCohort 1 received 2 dose levels, 5 and 100 mg, separated by a washout period of 7 days.

^bCohort 2 received 2 dose levels, 25 and 200 mg, separated by a washout period of 7 days.

^cCohort 3 received 2 dose levels, 50 and 400 mg, separated by a washout period of 7 days.

Abbreviation: SAD, single ascending dose; MAD, multiple ascending doses.